comprehensive -WSS

comprehensive

author：comprehensive 2025-09-27 23:52:50 - browse：6885

President Joe Biden talks in the Roosevelt Room of the White House, in front of a painting of Theodore Roosevelt on a horse back — politics coverage from STAT — President Biden MANDEL NGAN/AFP via Getty Images

WASHINGTON — The White House is throwing its support behind a controversial authority that allows the government to undermine patent rights for certain high-priced medicines. It’s an early step that could have major ramifications for the American pharmaceutical industry, depending on whether and how federal officials actually use the authority.

The administration issued a framework for the National Institutes of Health to more broadly use so-called “march-in rights” — a policy that allows it to invalidate patent rights from drugmakers whose products rely on federally funded research. The framework lays out when the agency might assert this authority, and endorse using a drug’s price in that determination.

“We’ll make clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard told reporters. “These authorities are in existing laws, the last administration just didn’t want to allow them to be used in this way.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： The simple reason for the increase in autism diagnosis

entertainment

knowledge

WSS

Belarusian journalist sentenced to 4 years in prison as crackdown continues

The simple reason for the increase in autism diagnosis

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

What affirmative action's end means to a medical student

AstraZeneca lung cancer study comes in below expectations

hotspot

comprehensive

leisure time

Anesthesiologist group: stop taking Ozempic before surgery

UpToDate has a racism problem: Dr. Stanley Goldfarb

The high cost of giving birth even with insurance

Synthetic human embryos? Researchers say term is overblown

Dobbs anniversary: the lost opportunity of abortion as health care

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

Alkermes shareholders re

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Tuskegee Airman Raymond Cassagnol dies at 102

Wikipedia

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Hubble vs. James Webb telescope images: See the difference

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Dexcom's push to bring CGM to type 2 diabetes patients

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

knowledge

entertainment

knowledge

hotspot